In a groundbreaking discovery, Chinese scientists have developed a new therapy that dramatically improves survival rates following exposure to acute radiation. Published in the journal Cell Death and Differentiation, the research offers promising hope for both victims of nuclear fallout and cancer patients undergoing high-dose radiotherapy.
The study, led by Sun Yirong, focuses on a crucial gene known as the Stimulator of Interferon Genes (Sting). This gene typically triggers cell death when DNA damage occurs due to radiation exposure. Researchers found that disabling the function of Sting in mice increased survival rates from just 11% to an impressive 67% after exposure to lethal doses of radiation.
Acute ionising radiation—whether from a nuclear disaster or as a side effect of intensive radiotherapy—can severely damage DNA, halt cell division, and weaken the immune system. One of the most dangerous outcomes of high radiation exposure is gastrointestinal syndrome (GIS), where the cells lining the intestines deteriorate, leading to severe digestive issues and, in many cases, death. Currently, there are no effective treatments available to prevent or reverse this condition.
The research team observed that mice without active Sting proteins experienced significantly less intestinal damage after radiation exposure. The rate of cell death in these mice dropped from 45% to just 12%, and the height of their intestinal villi—tiny projections that help absorb nutrients—was found to be 2.3 times greater than in mice with active Sting. This suggests that their digestive systems were better able to resist radiation damage.
The findings could pave the way for revolutionary treatments to protect individuals exposed to high levels of radiation, whether in the aftermath of a nuclear attack, an industrial accident, or during radiation therapy for cancer. Researchers believe this therapy could not only save lives in extreme radiation scenarios but also enhance the effectiveness of cancer treatments by reducing side effects linked to damage of healthy cells.
“The therapies developed based on the new discovery of Sting proteins have shown great potential in protecting against radiation injury, enhancing cancer radiotherapy, and improving cancer treatment overall,” said Sun Yirong.
This breakthrough comes at a time when global tensions have reignited fears of nuclear conflict. Studies have long suggested that in the event of a nuclear war, far more people would die from radiation fallout than from the initial explosion itself. Prolonged exposure can lead to DNA damage that impacts future generations, making this discovery potentially life-saving on a vast scale.
Beyond nuclear scenarios, the therapy also offers new hope for cancer patients, particularly those receiving intensive radiotherapy for abdominal and pelvic tumors. By preventing intestinal breakdown, this treatment could significantly improve patient outcomes and reduce the debilitating side effects often associated with cancer treatment.
Further research and clinical trials will be necessary before the therapy can be applied to humans, but the study marks a significant leap forward in the fields of radiation medicine and oncology. This breakthrough could reshape how the world responds to nuclear threats and transform cancer care for millions of patients worldwide.
